{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:15Z","timestamp":1792719855612,"version":"4.5.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008413","name":"Instrumentariumin Tiedes\u00e4\u00e4ti\u00f6","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008413","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","award":["61-6200"],"award-info":[{"award-number":["61-6200"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","award":["190116"],"award-info":[{"award-number":["190116"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","award":["191118"],"award-info":[{"award-number":["191118"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","award":["180132"],"award-info":[{"award-number":["180132"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"crossref","award":["290520"],"award-info":[{"award-number":["290520"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"crossref","award":["TYH2018214"],"award-info":[{"award-number":["TYH2018214"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"crossref","award":["TYH2019235"],"award-info":[{"award-number":["TYH2019235"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["333050"],"award-info":[{"award-number":["333050"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","award":["304667"],"award-info":[{"award-number":["304667"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,21]]},"abstract":"<jats:p>Some clinically significant prostate cancers are missed by MRI. We asked whether the tumor stroma in surgically treated localized prostate cancer lesions positive or negative with MRI are different in their cellular and molecular properties, and whether the differences are reflected to the clinical course of the disease.<\/jats:p>\n                  <jats:p>We profiled the stromal and immune cell composition of MRI-classified tumor lesions by applying multiplexed fluorescence IHC (mfIHC) and automated image analysis in a clinical cohort of 343 patients (cohort I). We compared stromal variables between MRI-visible lesions, invisible lesions, and benign tissue and assessed the predictive significance for biochemical recurrence (BCR) and disease-specific survival (DSS) using Cox regression and log-rank analysis. Subsequently, we carried out a prognostic validation of the identified biomarkers in a population-based cohort of 319 patients (cohort II).<\/jats:p>\n                  <jats:p>MRI true-positive lesions are different from benign tissue and MRI false-negative lesions in their stromal composition. CD163+ cells (macrophages) and fibroblast activation protein (FAP)+ cells were more abundant in MRI true-positive than in MRI false-negative lesions or benign areas. In MRI true-visible lesions, a high proportion of stromal FAP+ cells was associated with PTEN status and increased immune infiltration (CD8+, CD163+), and predicted elevated risk for BCR. High FAP phenotype was confirmed to be a strong indicator of poor prognosis in two independent patient cohorts using also conventional IHC.<\/jats:p>\n                  <jats:p>The molecular composition of the tumor stroma may determine whether early prostate lesions are detectable by MRI and associates with survival after surgical treatment.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>These findings may have a significant impact on clinical decision making as more radical treatments may be recommended for men with a combination of MRI-visible primary tumors and FAP+ tumor stroma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-21-0183","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T09:37:08Z","timestamp":1647941828000},"page":"172-181","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9652-7373","authenticated-orcid":true,"given":"Teijo","family":"Pellinen","sequence":"first","affiliation":[{"name":"1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-6254","authenticated-orcid":true,"given":"Kevin","family":"Sandeman","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Helsinki and Helsinki University Hospital, Finland."},{"name":"3Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Blom","sequence":"additional","affiliation":[{"name":"1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-6983","authenticated-orcid":true,"given":"Riku","family":"Turkki","sequence":"additional","affiliation":[{"name":"1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland."},{"name":"4Science for Life Laboratory, Department of Oncology & Pathology, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabrita","family":"Hemmes","sequence":"additional","affiliation":[{"name":"1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"V\u00e4lim\u00e4ki","sequence":"additional","affiliation":[{"name":"1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho","family":"Eineluoto","sequence":"additional","affiliation":[{"name":"3Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland."},{"name":"5Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-5307","authenticated-orcid":true,"given":"Anu","family":"Kentt\u00e4mies","sequence":"additional","affiliation":[{"name":"6Department of Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5555-6645","authenticated-orcid":true,"given":"Stig","family":"Nordling","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Helsinki and Helsinki University Hospital, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-0332","authenticated-orcid":true,"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[{"name":"1Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland."},{"name":"4Science for Life Laboratory, Department of Oncology & Pathology, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4261-3484","authenticated-orcid":true,"given":"Antti","family":"Rannikko","sequence":"additional","affiliation":[{"name":"3Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland."},{"name":"5Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland."},{"name":"7iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-9891","authenticated-orcid":true,"given":"Tuomas","family":"Mirtti","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Helsinki and Helsinki University Hospital, Finland."},{"name":"3Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland."},{"name":"7iCAN-Digital Precision Cancer Medicine Flagship, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eururo.2019.09.027","article-title":"Predicting prostate cancer death with different pretreatment risk stratification tools: A head-to-head comparison in a nationwide cohort study","volume":"77","author":"Zelic","year":"2020","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JU.0000000000000617","article-title":"Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer","volume":"203","author":"Bjurlin","year":"2020","journal-title":"J Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2018.05.035","article-title":"Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions","volume":"75","author":"Padhani","year":"2019","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"F\u00fctterer","year":"2015","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"181.e1","DOI":"10.1016\/j.urolonc.2018.10.026","article-title":"Adding multiparametric MRI to the MSKCC and partin nomograms for primary prostate cancer: Improving local tumor staging","volume":"37","author":"Jansen","year":"2019","journal-title":"Urol Oncol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2016.08.015","article-title":"The incremental role of magnetic resonance imaging for prostate cancer staging before radical prostatectomy","volume":"71","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.euf.2018.11.004","article-title":"Combined clinical parameters and multiparametric magnetic resonance imaging for the prediction of extraprostatic Disease-A risk model for patient-tailored risk stratification when planning radical prostatectomy","volume":"6","author":"Nyarangi-Dix","year":"2020","journal-title":"Eur Urol Focus"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00330-017-5031-5","article-title":"Optimising preoperative risk stratification tools for prostate cancer using mpMRI","volume":"28","author":"Reis\u00e6ter","year":"2018","journal-title":"Eur Radiol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","article-title":"Multiparametric MRI for prostate cancer diagnosis: current status and future directions","volume":"17","author":"Stabile","year":"2020","journal-title":"Nat Rev Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/jmri.26743","article-title":"Head-to-head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy","volume":"50","author":"Zanelli","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-Targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00330-015-3894-x","article-title":"What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?","volume":"26","author":"De Visschere","year":"2016","journal-title":"Eur Radiol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2017.03.042","article-title":"Diagnostic performance of magnetic resonance imaging for the detection of bone metastasis in prostate cancer: a systematic review and meta-analysis","volume":"73","author":"Woo","year":"2018","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1148\/radiol.2015142414","article-title":"Changes in epithelium, stroma, and lumen space correlate more strongly with gleason pattern and are stronger predictors of prostate ADC changes than cellularity metrics","volume":"277","author":"Chatterjee","year":"2015","journal-title":"Radiology"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/RLI.0b013e3181b4c10e","article-title":"Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla","volume":"44","author":"Gibbs","year":"2009","journal-title":"Invest Radiol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.12.036","article-title":"Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer","volume":"76","author":"Houlahan","year":"2019","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/radiol.2017152877","article-title":"What are we missing? False-negative cancers at multiparametric MR imaging of the prostate","volume":"286","author":"Borofsky","year":"2018","journal-title":"Radiology"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jmri.25716","article-title":"Quantified analysis of histological components and architectural patterns of gleason grades in apparent diffusion coefficient restricted areas upon diffusion weighted MRI for peripheral or transition zone cancer locations","volume":"46","author":"Helfrich","year":"2017","journal-title":"J Magn Reson Imaging"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1148\/radiol.10091343","article-title":"Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features","volume":"255","author":"Langer","year":"2010","journal-title":"Radiology"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41379-019-0292-y","article-title":"Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer","volume":"32","author":"Miyai","year":"2019","journal-title":"Mod Pathol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.juro.2012.01.074","article-title":"Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected","volume":"187","author":"Rosenkrantz","year":"2012","journal-title":"J Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/pros.23867","article-title":"Fibroblast as a critical stromal cell type determining prognosis in prostate cancer","volume":"79","author":"Blom","year":"2019","journal-title":"Prostate"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.euf.2020.06.016","article-title":"Associations of PTEN and ERG with magnetic resonance imaging visibility and assessment of non-organ-confined pathology and biochemical recurrence after radical prostatectomy","volume":"7","author":"Eineluoto","year":"2021","journal-title":"Eur Urol Focus"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/emboj.2011.328","article-title":"Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer","volume":"30","author":"Sahu","year":"2011","journal-title":"EMBO J"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"15580","DOI":"10.1038\/s41598-017-15798-4","article-title":"Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis","volume":"7","author":"Blom","year":"2017","journal-title":"Sci Rep"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.eururo.2019.04.043","article-title":"Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis","volume":"76","author":"Kasivisvanathan","year":"2019","journal-title":"Eur Urol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1158\/1078-0432.CCR-20-4217","article-title":"Single-cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer","volume":"27","author":"Pachynski","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"14269","DOI":"10.1038\/s41598-018-32549-1","article-title":"Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma","volume":"8","author":"Andersen","year":"2018","journal-title":"Sci Rep"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1530\/ERC-12-0085","article-title":"The reactive stroma microenvironment and prostate cancer progression","volume":"19","author":"Barron","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.humpath.2017.02.019","article-title":"Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3)","volume":"63","author":"De Vivar","year":"2017","journal-title":"Hum Pathol"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/pros.23831","article-title":"PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma)","volume":"79","author":"Shah","year":"2019","journal-title":"Prostate"},{"key":"2023030219504272200_","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/onc.2016.232","article-title":"Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer","volume":"36","author":"Su","year":"2017","journal-title":"Oncogene"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-21-0183\/3057581\/crc-21-0183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/3\/172\/3279380\/crc-21-0183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/3\/172\/3279380\/crc-21-0183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T23:24:42Z","timestamp":1700349882000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/3\/172\/694060\/Stromal-FAP-Expression-is-Associated-with-MRI"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,21]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-21-0183","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550682","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550682.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544537.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}